BridgeBio Pharma, Inc. (BBIO)

NASDAQ: BBIO · IEX Real-Time Price · USD
14.90
+1.32 (9.72%)
At close: Mar 24, 2023, 4:00 PM
16.75
+1.85 (12.42%)
After-hours: Mar 24, 2023, 7:59 PM EDT
9.72%
Market Cap 2.39B
Revenue (ttm) 77.65M
Net Income (ttm) -481.18M
Shares Out 160.20M
EPS (ttm) -3.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,501,471
Open 13.60
Previous Close 13.58
Day's Range 11.75 - 14.90
52-Week Range 4.98 - 19.95
Beta 0.63
Analysts Buy
Price Target 23.69 (+58.99%)
Earnings Date May 4, 2023

About BBIO

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 cli... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 27, 2019
Employees 576
Stock Exchange NASDAQ
Ticker Symbol BBIO
Full Company Profile

Financial Performance

In 2022, BBIO's revenue was $77.65 million, an increase of 11.38% compared to the previous year's $69.72 million. Losses were -$481.18 million, -14.46% less than in 2021.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for BBIO stock is "Buy." The 12-month stock price forecast is $23.69, which is an increase of 58.99% from the latest price.

Price Target
$23.69
(58.99% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb's OPDIVO® (nivolumab)

– BBP-398, an investigational SHP2 inhibitor, is a potentially best-in-class therapy for use in combination approaches, which is shown by preclinical findings demonstrating its safety profile, continu...

3 days ago - GlobeNewsWire

BridgeBio Pharma (BBIO) Surges 77% YTD: Here's Why

Shares of BridgeBio (BBIO) are up rising since the company announced positive data from a mid-stage study, which evaluated its experimental drug infigratinib in children with achondroplasia, a form of...

3 days ago - Zacks Investment Research

BridgeBio Pharma Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)

- BridgeBio has developed a validated bioassay that directly measures glycosylated ⍺ DG, which is central to LGMD2I disease, and enables monitoring of responses to disease-modifying therapies in LGMD2...

5 days ago - GlobeNewsWire

BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)

- BridgeBio will also share 15-month Phase 2 data and review the Phase 3 clinical trial design of BBP-418, a potential therapeutic for patients with LGMD2I, with initiation of its Phase 3 study expect...

1 week ago - GlobeNewsWire

BridgeBio's Volatile Week Puts Biotech Stocks Under a Microscope

The Palo Alto-based company's susceptibility to extreme price swings was on display again last week, albeit on a smaller scale. Positive results in a study of BridgeBio's infigratinib candidate sent t...

1 week ago - MarketBeat

Is BridgeBio Pharma (BBIO) Stock Outpacing Its Medical Peers This Year?

Here is how BridgeBio Pharma (BBIO) and Bio-Rad Laboratories (BIO) have performed compared to their sector so far this year.

2 weeks ago - Zacks Investment Research

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock

PALO ALTO, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today a...

2 weeks ago - GlobeNewsWire

BridgeBio Pharma Announces Proposed Public Offering of Common Stock

PALO ALTO, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announc...

2 weeks ago - GlobeNewsWire

Why Is BridgeBio Pharma (BBIO) Stock Up 60% Today?

There's potentially good news for the medical community and definitely positive news for investors of BridgeBio Pharma (NASDAQ: BBIO) stock. Reportedly, BridgeBio Pharma published clinical results fr...

2 weeks ago - InvestorPlace

BridgeBio's stock rallies 50% on new data from dwarfism therapy

Shares of BridgeBio Pharma Inc. BBIO, -0.09% soared about 52% in premarket trading on Monday after the company shared positive data from a Phase 2 clinical trial about its experimental treatment for a...

2 weeks ago - Market Watch

BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023

PALO ALTO, Calif., March 03, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today ann...

3 weeks ago - GlobeNewsWire

Does BridgeBio Pharma (BBIO) Have the Potential to Rally 67.36% as Wall Street Analysts Expect?

The consensus price target hints at a 67.4% upside potential for BridgeBio Pharma (BBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

3 weeks ago - Zacks Investment Research

BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -1.16% and 84.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update

–Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) continues to have high operating fidelity; month 30 topline registrational data are expected...

1 month ago - GlobeNewsWire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...

1 month ago - GlobeNewsWire

Will BridgeBio Pharma (BBIO) Report Negative Q4 Earnings? What You Should Know

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023

PALO ALTO, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...

1 month ago - GlobeNewsWire

BridgeBio Pharma to Participate in February and March Investor Events

PALO ALTO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...

1 month ago - GlobeNewsWire

BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference

PALO ALTO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...

2 months ago - GlobeNewsWire

BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1

- The CALIBRATE Phase 3 study design incorporates feedback from global regulatory agencies and will compare the effects of encaleret to standard of care on blood and urinary calcium concentrations ove...

3 months ago - GlobeNewsWire

BridgeBio Pharma to Participate in November Investor Events

PALO ALTO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...

4 months ago - GlobeNewsWire

BridgeBio Pharma (BBIO) Reports Q3 Loss, Misses Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 8.82% and 94.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update

- Reported positive preclinical data for its next-generation KRAS G12C GTP/GDP dual inhibitor development candidate, BBO-8520, and for its novel PI3Kα:RAS breaker mechanism in late lead optimization

5 months ago - GlobeNewsWire

Will BridgeBio Pharma (BBIO) Report Negative Q3 Earnings? What You Should Know

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative Symposium

- BridgeBio to host investor call today (October 17, 2022) at 1:30 pm ET to discuss its two most advanced RAS precision oncology programs – KRAS G12C GTP/GDP dual inhibitor development candidate BBO-8...

5 months ago - GlobeNewsWire